Literature DB >> 6538490

Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ).

C L King, S K Wong, T L Loo.   

Abstract

The bifunctional cross-linking activity of 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ, NSC 182986) on isolated calf thymus DNA was studied, using ethidium bromide fluorescence assay. Between 1 and 350 microM AZQ produced a dose-dependent cross-linking effect in the presence of a 10-fold excess of sodium borohydride. No cross-linking was observed in the absence of the reducing agent. AZQ can also be activated by NADH and NADPH at pH 4. The AZQ cross-linking activity exhibited a strong pH dependency, highest at acidic pH, lower at alkaline pH and not seen under neutral conditions. It was also significantly inhibited under anaerobic conditions. At pH 5 the binding ratio was 1 molecule of AZQ per 191 bases at an AZQ dose of 300 microM. Our results suggest that reduced AZQ behaved like a bifunctional alkylating agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538490     DOI: 10.1016/0277-5379(84)90193-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.

Authors:  R P Castleberry; A H Ragab; C P Steuber; B Kamen; S Toledano; K Starling; D Norris; P Burger; J P Krischer
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

Review 2.  Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?

Authors:  J Butler; B M Hoey
Journal:  Br J Cancer Suppl       Date:  1987-06

3.  In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.

Authors:  R M Phillips; P B Hulbert; M C Bibby; N R Sleigh; J A Double
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.